hydrochlorothiazide has been researched along with Ventricular Dysfunction, Left in 9 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function." | 9.09 | Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. ( Brilla, CG; Funck, RC; Rupp, H, 2000) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 6.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| "In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function." | 5.09 | Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. ( Brilla, CG; Funck, RC; Rupp, H, 2000) |
| "This review focuses on the role of the fixed-dose combination (FDC) drug valsartan/hydrochlorothiazide (HCTZ) in the treatment of hypertension." | 4.87 | Valsartan plus hydrochlorothiazide: a review of its use since its introduction. ( Bains, J; Smith, WB, 2011) |
| "Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks." | 2.82 | Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. ( Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016) |
| "Hypertension is associated with an increased risk of diastolic dysfunction." | 2.77 | Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Kasayuki, N; Kihara, H; Nakamura, F; Shimada, K; Yoshikawa, J, 2012) |
| "Hydrochlorothiazide was added when need to achieve blood pressure control." | 2.77 | Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals. ( Armendaris, MK; Beck, AL; D'Avila, LB; Netto, FM; Otto, ME; Sposito, AC, 2012) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 2.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toh, N | 1 |
| Ishii, K | 2 |
| Kihara, H | 2 |
| Iwakura, K | 2 |
| Watanabe, H | 1 |
| Yoshikawa, J | 2 |
| Ito, H | 2 |
| Ogunyankin, KO | 1 |
| Day, AG | 1 |
| Bains, J | 1 |
| Smith, WB | 1 |
| Kasayuki, N | 1 |
| Nakamura, F | 1 |
| Shimada, K | 1 |
| Fukuda, S | 1 |
| Beck, AL | 1 |
| Otto, ME | 1 |
| D'Avila, LB | 1 |
| Netto, FM | 1 |
| Armendaris, MK | 1 |
| Sposito, AC | 1 |
| Rinder, MR | 1 |
| Spina, RJ | 1 |
| Peterson, LR | 1 |
| Koenig, CJ | 1 |
| Florence, CR | 1 |
| Ehsani, AA | 1 |
| Little, WC | 1 |
| Zile, MR | 1 |
| Klein, A | 1 |
| Appleton, CP | 1 |
| Kitzman, DW | 1 |
| Wesley-Farrington, DJ | 1 |
| Brilla, CG | 1 |
| Funck, RC | 1 |
| Rupp, H | 1 |
| Palmieri, V | 1 |
| Devereux, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures[NCT00229242] | 38 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction[NCT01061450] | Phase 4 | 55 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydrochlorothiazide and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2011 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
7 trials available for hydrochlorothiazide and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2016 |
Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydr | 2009 |
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2012 |
Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Brazi | 2012 |
Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults.
Topics: Aged; Angiotensins; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Compo | 2004 |
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Echocardiography, | 2006 |
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |